Search details
1.
Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer.
N Engl J Med
; 385(5): 395-405, 2021 07 29.
Article
in English
| MEDLINE | ID: mdl-34320285
2.
Conventional versus reverse sequence of neoadjuvant epirubicin/cyclophosphamide and docetaxel: sequencing results from ABCSG-34.
Br J Cancer
; 124(11): 1795-1802, 2021 05.
Article
in English
| MEDLINE | ID: mdl-33762716
3.
Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 20(3): 339-351, 2019 03.
Article
in English
| MEDLINE | ID: mdl-30795951
4.
Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial.
Lancet
; 386(9992): 433-43, 2015 Aug 01.
Article
in English
| MEDLINE | ID: mdl-26040499
5.
Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor Response.
Clin Cancer Res
; 28(4): 697-707, 2022 02 15.
Article
in English
| MEDLINE | ID: mdl-34862246
6.
Long-Term Outcomes of Adjuvant Denosumab in Breast Cancer.
NEJM Evid
; 1(12): EVIDoa2200162, 2022 Dec.
Article
in English
| MEDLINE | ID: mdl-38319865
7.
Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03).
J Clin Oncol
; 40(5): 449-458, 2022 02 10.
Article
in English
| MEDLINE | ID: mdl-34995105
8.
The EndoPredict score predicts response to neoadjuvant chemotherapy and neoendocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients from the ABCSG-34 trial.
Eur J Cancer
; 134: 99-106, 2020 07.
Article
in English
| MEDLINE | ID: mdl-32502940
9.
Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomised, neoadjuvant phase II study (ABCSG 34).
Eur J Cancer
; 132: 43-52, 2020 06.
Article
in English
| MEDLINE | ID: mdl-32325419
10.
Endocrine therapy with or without whole breast irradiation in low-risk breast cancer patients after breast-conserving surgery: 10-year results of the Austrian Breast and Colorectal Cancer Study Group 8A trial.
Eur J Cancer
; 127: 12-20, 2020 03.
Article
in English
| MEDLINE | ID: mdl-31962198
11.
The potential risk of neoadjuvant chemotherapy in breast cancer patients--results from a prospective randomized trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-07).
Breast Cancer Res Treat
; 112(2): 309-16, 2008 Nov.
Article
in English
| MEDLINE | ID: mdl-18080748
12.
Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer--Austrian Breast and Colorectal Cancer Study Group Trial 5.
J Clin Oncol
; 20(24): 4621-7, 2002 Dec 15.
Article
in English
| MEDLINE | ID: mdl-12488405
13.
Randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide as adjuvant treatment in postmenopausal breast cancer patients with hormone receptor-positive disease: Austrian breast and colorectal cancer study group trial 6.
J Clin Oncol
; 21(6): 984-90, 2003 Mar 15.
Article
in English
| MEDLINE | ID: mdl-12637461
Results
1 -
13
de 13
1
Next >
>>